Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2020

View Archived Issues

SERPINB3 targeting proven useful for treating NASH

Benzodiazepine and barbiturate binding to GABA-A

Giving misfolded proteins a second chance

Agrin-culture grows cartilage

SCAD versus plaques in heart attacks

Zion initiates phase I study in U.S. with ZN-A-1041

FDA approves Detectnet

New personalized cystic fibrosis treatment treats Class V mutations

First patient dosed in triple combination study of COM-701 plus Opdivo and BMS-986207

Arcutis accelerates ARQ-151 into phase III trials for the treatment of atopic dermatitis

First phase I data presented for the neutrophil elastase inhibitor BI-1323495

Opaganib demonstrates complete inhibition of SARS-CoV-2 in vitro

First subject dosed in phase I study of ALLN-346

Positive and statistically significant topline data from the pivotal LOGICS study of Recorlev

Enrollment begins in phase I study of AG-946

Phase III trial of odevixibat in progressive familial intrahepatic cholestasis meets endpoints

Janssen describes new anti-hepatitis B virus compounds

Asceneuron discovers N-acetyl-beta-D-glucosaminidase inhibitors

Sichuan Kelun-Biotech Biopharmaceutical patents NLRP3 agonists

Results from a phase IIa POC trial of the oral adenosine A1 receptor antagonist PBF-680

New thyroid hormone receptor alpha/beta agonists discovered at Nanjing Ruijie Pharma

Cervello Therapeutics describes new Rho-associated protein kinase inhibitors

Immunocore's bispecific ImmTAV molecules eliminate HBV-infected cells

Argenx begins first-in-human study of ARGX-117

LNC obtains IND clearance for phase I trial of Xla-1 for obesity

FDA clears IND for phase I study of anti-CD19 CAR-T cell therapy CB-010 for B-NHL

FDA accepts IND for phase I study of ATA-2271 for advanced mesothelioma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 7, 2025.
House passes H.R. 1, restoring R&D tax cuts
BioWorld MedTech
The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
With surface mimicry, molecular glues shed hairpin need
BioWorld Science
Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...